Reduced morbidity and mortality in the first year after initiating highly active anti-retroviral therapy (HAART) among Ugandan adults

Simple item page
dc.contributor.authorMiiro, George
dc.contributor.authorTodd, Jim
dc.contributor.authorMpendo, Juliet
dc.contributor.authorWatera, Christine
dc.contributor.authorMunderi, Paula
dc.contributor.authorNakubulwa, Susan
dc.contributor.authorKaddu, Ismael
dc.contributor.authorRutebarika, Diana
dc.contributor.authorGrosskurth, Heiner
dc.date.accessioned2022-05-17T18:06:59Z
dc.date.available2022-05-17T18:06:59Z
dc.date.issued2009
dc.description.abstractTo evaluate the effect of highly active anti-retroviral therapy (HAART) and cotrimoxazole prophylaxis on morbidity after HAART eligibility. methods Between 1999 and 2006, we collected morbidity data from a community-based cohort of HAART-eligible patients, comparing patients initiating HAART and those non-HAART. Patients aged 15 years or older visited the clinic every 6 months and when ill. Baseline data on patients’ characteristics, WHO stage, haemoglobin and CD4+ T-cell counts, along with follow-up data on morbidity (new, recurrent and drug-related), were collected for the first year after initiating HAART or becoming HAART-eligible. We estimated the overall effect of HAART on morbidity; adjusted for the effect of cotrimoxazole prophylaxis by Mantel–Haenszel methods. A negative binomial regression model was used to assess rate ratios (RR) after adjustment for other confounders, including cotrimoxazole. results A total of 219 HAART patients (median age 37 years; 73% women; 82% using cotrimoxazole prophylaxis, median haemoglobin 11.7 g ⁄ dl and median CD4+ 131 cells ⁄ ll) experienced 94 events in 127 person-years. 616 non-HAART patients (median age 33 years; 70% women; 26% using cotrimoxazole prophylaxis, median haemoglobin 11.2 g ⁄ dl and median CD4+ 130 cells ⁄ ll) experienced 862 events in 474 person-years. The overall morbidity during the first year of HAART was 80% lower than among non-HAART patients (adjusted RR = 0.20, 95% CI: 0.12–0.34). Cotrimoxazole prophylaxis also reduced morbidity (adjusted RR = 0.65, 95% CI: 0.45–0.94). conclusion These results confirm the reduction in morbidity due to HAART, and the additional protection of cotrimoxazole prophylaxis.en_US
dc.identifier.citationMiiro, G., Todd, J., Mpendo, J., Watera, C., Munderi, P., Nakubulwa, S., ... & Grosskurth, H. (2009). Reduced morbidity and mortality in the first year after initiating highly active anti‐retroviral therapy (HAART) among Ugandan adults. Tropical Medicine & International Health, 14(5), 556-563. doi:10.1111/j.1365-3156.2009.02259.xen_US
dc.identifier.other10.1111/j.1365-3156.2009.02259.x
dc.identifier.urihttps://nru.uncst.go.ug/handle/123456789/3251
dc.language.isoenen_US
dc.publisherTropical Medicine & International Healthen_US
dc.subjectHighly active anti-retroviral therapyen_US
dc.subjectCotrimoxazole prophylaxisen_US
dc.subjectMorbidityen_US
dc.subjectAdverse eventsen_US
dc.titleReduced morbidity and mortality in the first year after initiating highly active anti-retroviral therapy (HAART) among Ugandan adultsen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Tropical Med Int Health - 2009 - Miiro - Reduced morbidity and mortality in the first year after initiating highly active.pdf
Size:
62.39 KB
Format:
Adobe Portable Document Format
Description:
Article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Medical and Health Sciences